Leif W Ellisen
Overview
Explore the profile of Leif W Ellisen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
8212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Medford A, Ellisen L
JCO Precis Oncol
. 2024 Jan;
8():e2300609.
PMID: 38271658
We discuss a recent manuscript providing recommendations to improve use and access for liquid biopsy in oncology.
12.
Spring L, Mortensen L, Abraham E, Keenan J, Medford A, Ma A, et al.
JCO Oncol Pract
. 2023 Nov;
20(1):69-76.
PMID: 37922440
Purpose: There is a demand for improved care delivery surrounding genomic testing and clinical trial enrollment among patients with metastatic breast cancer (MBC). We sought to improve the current process...
13.
Bukhari S, Truesdell S, Datta C, Choudhury P, Wu K, Shrestha J, et al.
bioRxiv
. 2023 Jun;
PMID: 37292633
Our data previously revealed that chemosurviving cancer cells translate specific genes. Here, we find that the m6A-RNA-methyltransferase, METTL3, increases transiently in chemotherapy-treated breast cancer and leukemic cells in vitro and...
14.
Brett J, Dubash T, Johnson G, Niemierko A, Mariotti V, Kim L, et al.
JCO Precis Oncol
. 2023 May;
7:e2200532.
PMID: 37141550
Purpose: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), first-line treatment is endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibition (CDK4/6i)....
15.
Dai C, Ellisen L
Oncologist
. 2023 Mar;
28(5):383-391.
PMID: 36972361
Aberrant estrogen receptor (ER) signaling is central to the pathogenesis of many breast cancers. Like ER, the androgen receptor (AR) is a steroid nuclear receptor that is frequently expressed in...
16.
Abelman R, Wu B, Spring L, Ellisen L, Bardia A
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831621
Antibody-drug conjugates (ADCs), with antibodies targeted against specific antigens linked to cytotoxic payloads, offer the opportunity for a more specific delivery of chemotherapy and other bioactive payloads to minimize side...
17.
Medford A, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, et al.
Ther Adv Med Oncol
. 2023 Feb;
15:17588359231152844.
PMID: 36743521
Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab and the TRK...
18.
Brett J, Ritterhouse L, Newman E, Irwin K, Dawson M, Ryan L, et al.
Oncologist
. 2022 Dec;
28(2):172-179.
PMID: 36493359
In hormone receptor-positive metastatic breast cancer (HR+ MBC), endocrine resistance is commonly due to genetic alterations of ESR1, the gene encoding estrogen receptor alpha (ERα). While ESR1 point mutations (ESR1-MUT)...
19.
Wu B, Ellisen L
Cancer Cell
. 2022 Nov;
40(11):1276-1278.
PMID: 36379206
A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of...
20.
Denault E, Nakajima E, Naranbhai V, Hutchinson J, Mortensen L, Neihoff E, et al.
Ther Adv Med Oncol
. 2022 Sep;
14:17588359221119370.
PMID: 36051470
Purpose: To explore the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with breast cancer based on type of anticancer treatment. Methods: Patients with breast cancer...